Table 3.
Univariate and multivariate analyses for risk factors associated with PFS/DFS and OS
| N | Median PFS/DFS (days) | Univariate analysis, P-value | Multivariate analysis
|
Median OS (days) | Univariate analysis, P-value | Multivariate analysis
|
|||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||||||
|
| |||||||||
| Age, years | 0.95 | 0.86 | |||||||
| <60 | 148 | 349 | NR | ||||||
| ≥60 | 108 | 488 | NR | ||||||
| Gender | 0.52 | 0.17 | |||||||
| Male | 108 | 420 | NR | ||||||
| Female | 148 | 365 | NR | ||||||
| KPS | 0.001 | 0.60 (0.44–0.82) | 0.31 | 0.005 | 0.57 (0.38–0.85) | 0.22 | |||
| <90 | 92 | 301 | 953 | ||||||
| ≥90 | 164 | 488 | NR | ||||||
| Smoking status | 0.06 | 0.06 | |||||||
| Never | 179 | 353 | NR | ||||||
| Ever | 77 | 488 | NR | ||||||
| Clinical stage | <0.001 | 2.80 (1.92–4.80) | <0.001 | <0.001 | 2.14 (1.01–4.51) | 0.046 | |||
| 1–3 | 118 | 594 | NR | ||||||
| 4 | 138 | 279 | 557 | ||||||
| Tumor location | <0.001 | 0.67 (0.48–0.94) | 0.02 | <0.001 | 2.14 (1.01–4.51) | 0.002 | |||
| Central | 124 | 301 | 734 | ||||||
| Peripheral | 132 | 550 | NR | ||||||
| EGFR status | 0.048 | 0.71 (0.51–1.00) | 0.049 | <0.001 | 0.20 (0.12–0.32) | <0.001 | |||
| Wild-type | 124 | 316 | 641 | ||||||
| Mutant-type | 132 | 487 | NR | ||||||
| Mutation type | 0.47 | 0.63 | |||||||
| 19 del | 52 | 487 | NR | ||||||
| 21 L858R | 75 | 420 | NR | ||||||
| CEA (ng/mL) | 0.02 | 1.45 (1.05–2.00) | 0.63 | 0.06 | |||||
| High (>6.7) | 120 | 323 | NR | ||||||
| Low (<6.7) | 123 | 449 | NR | ||||||
| LDH (U/L) | 0.04 | 1.39 (1.01–1.91) | 0.70 | 0.12 | |||||
| High (>188) | 119 | 365 | NR | ||||||
| Low (<188) | 124 | 449 | NR | ||||||
| LMR | 0.01 | 0.67 (0.49–0.91) | 0.10 | 0.04 | 0.66 (0.44–1.00) | 0.83 | |||
| High (>3.15) | 126 | 488 | NR | ||||||
| Low (<3.15) | 128 | 346 | NR | ||||||
| Surgery | <0.001 | 0.40 (0.29–0.56) | 0.12 | <0.001 | 0.36 (0.16–0.79) | 0.01 | |||
| Yes | 112 | 600 | NR | ||||||
| No | 144 | 280 | 654 | ||||||
| Response to first-line treatment | 0.18 | 0.33 | |||||||
| CR + PR | 77 | 320 | 734 | ||||||
| SD + PD | 79 | 241 | 601 | ||||||
| Contralateral pulmonary metastasis | 0.09 | 0.04 | 1.58 (1.02–2.43) | 0.77 | |||||
| No | 185 | 420 | NR | ||||||
| Yes | 71 | 301 | 826 | ||||||
| Visceral pleural nodule | 0.44 | 0.15 | |||||||
| No | 158 | 420 | NR | ||||||
| Yes | 98 | 365 | 953 | ||||||
| Interlobar pleural nodule | 0.32 | 0.008 | 1.83 (1.16–2.88) | 0.16 | |||||
| No | 201 | 353 | NR | ||||||
| Yes | 55 | 487 | 826 | ||||||
| Pleural effusion | <0.001 | 1.85 (1.32–2.59) | 0.30 | <0.001 | 2.24 (1.47–3.39) | 0.13 | |||
| No | 187 | 421 | NR | ||||||
| Yes | 69 | 301 | 557 | ||||||
| COPD | 0.048 | 1.59 (1.00–2.55) | 0.27 | 0.02 | 1.83 (1.00–3.32) | 0.048 | |||
| No | 228 | 403 | NR | ||||||
| Yes | 28 | 203 | 310 | ||||||
| ILD | <0.001 | 1.87 (1.29–2.70) | 0.001 | <0.001 | 2.43 (1.55–3.81) | <0.001 | |||
| No | 188 | 508 | NR | ||||||
| Yes | 68 | 241 | 557 | ||||||
Abbreviations: CEA, carcino-embryonic antigen; ILD, interstitial lung disease; CR, complete response; KPS, Karnofsky Performance Status; LDH, lactate dehydrogenase; LMR, lymphocyte–monocyte ratio; NR, not reached; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; DFS, disease-free survival.